东诚药业(002675) - 东诚药业投资者关系管理信息

Group 1: Financial Performance - In the first half of 2024, the company achieved operating revenue of 1.421 billion yuan, a year-on-year decrease of 20.41% [2] - The net profit attributable to shareholders was 112 million yuan, down 39.35% year-on-year [2] - The sales revenue of the nuclear medicine segment was 499 million yuan, a decline of 0.58% [2] - Key product 18 F-FDG generated revenue of 195 million yuan, down 4.30% [2] - The iodine raw material drug segment reported sales of 657 million yuan, a decrease of 31.03% [2] - The sales revenue of the formulation segment was 179 million yuan, down 32.01% [2] Group 2: Product Development and Clinical Trials - The company is conducting Phase III clinical trials for 18 F-LNC1001 injection [2] - 18 F-LNC1005 injection has completed Phase I clinical trials [2] - 177 Lu-LNC1004 injection is undergoing clinical trials in China and Singapore [2] - 8 nuclear medicine production centers are currently under construction, with a total of 30 operational centers covering 93.5% of the domestic nuclear medicine demand [2]